David Ricks, Eli Lilly CEO (Carolyn Kaster/AP Images)

Lil­ly gears up trio of PhI­II tri­als for its oral GLP-1 amid No­vo Nordisk, Pfiz­er com­pe­ti­tion

As No­vo Nordisk and Pfiz­er dis­close some da­ta on their oral weight loss drugs in Phase III and II, re­spec­tive­ly, Eli Lil­ly is beef­ing up its stance in the obe­si­ty field with three late-stage clin­i­cal tri­als of its next-gen­er­a­tion GLP-1 ag­o­nist or­for­glipron.

The moves, dis­closed in up­dates to the fed­er­al clin­i­cal tri­als data­base this week, put the In­di­anapo­lis drug­mak­er ahead of Pfiz­er, whose sci­ence chief has said the com­pa­ny will “cher­ry-pick” which of its mid-stage can­di­dates to take deep­er in­to the clin­ic af­ter da­ta late this year or ear­ly next.

Endpoints News

Unlock this article instantly by becoming a free subscriber.

You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.